- Home
- XBIT vs BBBYW Comparison
XBIT vs BBBYW Comparison
Compare XBIT & BBBYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XBIT | BBBYW |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Catalog/Specialty Distribution |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.1M | 59.2M |
| IPO Year | 2015 | 2002 |
Fundamental Metrics
Financial Performance| Metric | XBIT | BBBYW |
|---|---|---|
| Price | $2.20 | $0.83 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 45.0K | ★ 348.4K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.64 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,044,616,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.09 | $0.52 |
| 52 Week High | $3.44 | $1.20 |
Technical Indicators
Market Signals| Indicator | XBIT | BBBYW |
|---|---|---|
| Relative Strength Index (RSI) | 40.99 | N/A |
| Support Level | $2.21 | N/A |
| Resistance Level | $2.46 | N/A |
| Average True Range (ATR) | 0.07 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 11.76 | 0.00 |
Price Performance
Historical ComparisonAbout XBIT XBiotech Inc.
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.